2. Search Result
Search Result
Results for "

6-16

" in MedChemExpress (MCE) Product Catalog:

46

Inhibitors & Agonists

7

Fluorescent Dye

2

Biochemical Assay Reagents

2

Peptides

9

Natural
Products

2

Isotope-Labeled Compounds

2

Antibodies

13

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3155
    Ac-hMCH(6-16)-NH2

    		MCHR1 (GPR24) Metabolic Disease
    Ac-hMCH(6-16)-NH2 binds to and activates equally well both human MCH receptors present in the brain (non-selective agonist), with IC50 values of 0.16 nM and 2.7 nM for MCH-1R and MCH-2R .
    Ac-hMCH(6-16)-NH2
  • HY-114419
    Zetomipzomib
    1 Publications Verification

    KZR-616

    		 Proteasome Inflammation/Immunology
    Zetomipzomib (KZR-616), a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. Zetomipzomib has the potential for the research of multiple autoimmune diseases .
    Zetomipzomib
  • HY-114419A
    Zetomipzomib maleate
    1 Publications Verification

    KZR-616 maleate

    		 Proteasome Inflammation/Immunology
    Zetomipzomib (KZR-616) maleate, a first-in-class immunoproteasome inhibitor, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP2/mLMP2) subunits of the immunoproteasome. Zetomipzomib maleate has the potential for the research of multiple autoimmune diseases .
    Zetomipzomib maleate
  • HY-RS06558
    IFI6 Human Pre-designed siRNA Set A

    6-16; G1P3; FAM14C; IFI616; IFI-6-16

    		 Small Interfering RNA (siRNA) Others

    IFI6 Human Pre-designed siRNA Set A contains three designed siRNAs for IFI6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IFI6 Human Pre-designed siRNA Set A
    IFI6 Human Pre-designed siRNA Set A
  • HY-126291
    GNE-616

    		Sodium Channel Neurological Disease
    GNE-616 is a highly potent, metabolically stable, orally bioavailable, and subtype selective Nav1.7 inhibitor (Ki of 0.79 nM and Kd of 0.38 nM for hNav1.7) for the treatment of chronic pain. GNE-616 shows >1000 nM Kd and >2500-fold selectivity over hNav1.1, hNav1.3, hNav1.4, and hNav1.5. Selectivity over hNav1.2 and hNav1.6 is more modest at 31- and 73-fold, respectively .
    GNE-616
  • HY-W800780
    (6Z,16Z)-12-((Z)-Dec-4-enyl)docosa-6,16-dien-11-ol

    		Biochemical Assay Reagents Others
    (6Z,16Z)-12-(Z)-dec-4-enyl)docosa-6,16-dien-11-ol is an intermediate for the synthesis of lipid molecules.
    (6Z,16Z)-12-((Z)-Dec-4-enyl)docosa-6,16-dien-11-ol
  • HY-R01883
    hsa-miR-616-3p mimic

    		MicroRNA Cancer
    hsa-miR-616-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-616-3p mimic
    hsa-miR-616-3p mimic
  • HY-R01885
    hsa-miR-616-5p mimic

    		MicroRNA Cancer
    hsa-miR-616-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-616-5p mimic
    hsa-miR-616-5p mimic
  • HY-RI01885
    hsa-miR-616-5p inhibitor

    		MicroRNA Cancer
    hsa-miR-616-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-616-5p inhibitor
    hsa-miR-616-5p inhibitor
  • HY-RI01883
    hsa-miR-616-3p inhibitor

    		MicroRNA Cancer
    hsa-miR-616-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-616-3p inhibitor
    hsa-miR-616-3p inhibitor
  • HY-N1674
    2,6,16-Kauranetriol

    		Others Others
    2,6,16-Kauranetriol is a Diterpenoids product that can be isolated from the herbs of Pteris cretica .
    2,6,16-Kauranetriol
  • HY-R01883A
    hsa-miR-616-3p agomir

    		MicroRNA Cancer
    hsa-miR-616-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-616-3p agomir
    hsa-miR-616-3p agomir
  • HY-R01885A
    hsa-miR-616-5p agomir

    		MicroRNA Cancer
    hsa-miR-616-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-616-5p agomir
    hsa-miR-616-5p agomir
  • HY-RI01883A
    hsa-miR-616-3p antagomir

    		MicroRNA Cancer
    hsa-miR-616-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-616-3p antagomir
    hsa-miR-616-3p antagomir
  • HY-RI01885A
    hsa-miR-616-5p antagomir

    		MicroRNA Cancer
    hsa-miR-616-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-616-5p antagomir
    hsa-miR-616-5p antagomir
  • HY-156630
    Ionizable lipid-1
    1 Publications Verification

    		 Liposome Others
    Ionizable lipid-1 (compound II-10) is an ionizable lipid (pKa=6.16) that can be used to prepare lipid nanoparticles (LNP) with bilayer structure .
    Ionizable lipid-1
  • HY-156630A
    Ionizable lipid-1 hydrochloride

    		Liposome Others
    Ionizable lipid-1 (compound II-10) is an ionizable lipid (pKa=6.16) that can be used to prepare lipid nanoparticles (LNP) with bilayer structure .
    Ionizable lipid-1 hydrochloride
  • HY-N1675
    2,6,16-Kauranetriol 2-O-beta-D-allopyranoside

    		Others Others
    2,6,16-Kauranetriol 2-O-beta-D-allopyranoside is a Diterpenoids product that can be isolated from the herbs of Pteris cretica .
    2,6,16-Kauranetriol 2-O-beta-D-allopyranoside
  • HY-N3635
    Corymbol

    (6β)-Kaurane-6,16,17-triol; Corimbol

    		 Others Others
    Corymbol ((6β)-Kaurane-6,16,17-triol) is a Diterpenoids product that can be isolated from the herbs of Wedelia trilobata .
    Corymbol
  • HY-N4110R
    Friedelin (Standard)

    		Reference Standards Cytochrome P450 Metabolic Disease
    Friedelin (Standard) is the analytical standard of Friedelin. This product is intended for research and analytical applications. Friedelin is isolated from isolated from the leaves of Maytenus ilicifolia(Mart). Friedelin is a noncompetitive inhibitor of CYP3A4 with IC50 and Kivalues of 10.79 ?μM and 6.16? μM, respectively. Friedelin is also a competitive inhibitor of CYP2E1 with IC50 and Ki values of 22.54? μM and 18.02 μM, respectively .
    Friedelin (Standard)
  • HY-151254
    CYP2C19-IN-1

    		Cytochrome P450 Influenza Virus DNA/RNA Synthesis Infection
    CYP2C19-IN-1 (compound 20d) is a potent CYP2C19 inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C19-IN-1 inhibits RNA-dependent RNA polymerase (RdRP) with a Ki value of 6.16 µM. CYP2C19-IN-1 can be used in study of anti-ZIKV .
    CYP2C19-IN-1
  • HY-N4110
    Friedelin
    1 Publications Verification

    		 Cytochrome P450 NF-κB Interleukin Related Neurological Disease Metabolic Disease Inflammation/Immunology
    Friedelin is derived from the leaves of Maytenus ilicifolia (Mart). Friedelin is an orally active non-competitive inhibitor of CYP3A4, with IC50 and Ki values of 10.79 μM and 6.16 μM, respectively. Friedelin is also a competitive inhibitor of CYP2E1, with IC50 and Ki values of 22.54 μM and 18.02 μM, respectively. Friedelin can be used in research related to inflammation, neurological diseases, and metabolic disorders .
    Friedelin
  • HY-D1978
    ATTO 610 biotin

    		Fluorescent Dye Others
    ATTO 610 Biotin is a biotin derivative of ATTO 610 with maximum excitation/emission wavelengths: 616/633 nm.
    ATTO 610 biotin
  • HY-D1972
    ATTO 610 carboxy

    		Fluorescent Dye Others
    ATTO 610 Carboxy is a carboxyl derivative of ATTO 610 with maximum excitation/emission wavelengths: 616/633 nm.
    ATTO 610 carboxy
  • HY-D1977
    ATTO 610 streptavidin

    		Fluorescent Dye Others
    ATTO 610 Streptavidin is a streptavidin derivative of ATTO 610, it can label protein or antibody, the maximum excitation/emission wavelength: 616/633 nm.
    ATTO 610 streptavidin
  • HY-119733
    BU09059

    		Opioid Receptor Neurological Disease
    BU09059 is a potent and selective Kappa-opioid receptor antagonist with a pA2 of 8.62. BU09059 has nanomolar affinity for the κ-receptor, with 15-fold and 616-fold selectivity over μ- and δ-receptors, respectively. BU09059 significantly blocks U50488 (HY-15997B)-induced antinociception .
    BU09059
  • HY-D1976
    ATTO 610 maleimid

    		Fluorescent Dye Others
    ATTO 610 Maleimid is a maleimide ester derivative of ATTO 610, which can be used to label proteins or antibodies, with maximum excitation/emission wavelengths: 616/633 nm.
    ATTO 610 maleimid
  • HY-D1974
    ATTO 610 NHS-ester

    		Fluorescent Dye Others
    ATTO 610 NHS-Ester is an activated ester derivative of ATTO 610, which can directly label proteins or antibodies. The maximum excitation/emission wavelength: 616/633 nm.
    ATTO 610 NHS-ester
  • HY-149632
    EGFR/HER2/DHFR-IN-2

    		EGFR Dihydrofolate reductase (DHFR) Cancer
    EGFR/HER2/DHFR-IN-2 (Compound 4b) is an inhibitor of EGFR, HER2, and DHFR (IC50: 0.248, 0.156, 0.138 μM respectively). EGFR/HER2/DHFR-IN-2 has anticancer activities against a panel of cancer cells (IC50: 9.14, 7.33, 14.18, 24.87, 20.07, 6.16 μM for Hep G2, HeLa, HEp-2, HCT 116, PC-3, MCF7 cells). EGFR/HER2/DHFR-IN-2 reduce breast cancer tumor growth .
    EGFR/HER2/DHFR-IN-2
  • HY-D2042
    ATTO 610

    		Fluorescent Dye Others
    ATTO 610 is a new type of fluorescent dye with high fluorescence yield, which can be used for most labeling applications, maximum excitation/emission wavelength: 616/633 nm.
    ATTO 610
  • HY-D1735
    BODIPY TR Ceramide

    Golgi-Red Tracke

    		 Fluorescent Dye Others
    The Golgi apparatus is composed of flattened vesicles superimposed on each other by unit membranes. The flattened vesicles are round with expanded and perforated edges. The Golgi fluorescent probe is a BODIPY-labeled ceramide derivative, the synthesis of which occurs in the endoplasmic reticulum and can then be transported to the Golgi via ceramide transport protein (CERT) or vesicular translocation, allowing specific labeling of the dye. BODIPY TR Ceramide (Golgi-Red Tracke) is a Golgi-specific fluorescent dye, which can visualise individual cells . Ex/Em=589 nm/616 nm.
    BODIPY TR Ceramide
  • HY-RS22056
    Zdhhc19 Mouse Pre-designed siRNA Set A

    Gm616; Gm1744

    		 Small Interfering RNA (siRNA) Others

    Zdhhc19 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Zdhhc19 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Zdhhc19 Mouse Pre-designed siRNA Set A
    Zdhhc19 Mouse Pre-designed siRNA Set A
  • HY-N14028
    Coriolin A

    		Bacterial Infection Cancer
    Coriolin A has anti-Gram-positive bacteria, negative bacteria (weak), yeast and vaginal trichomoniasis activities. Coriolin A of 5 μg/mL can inhibit the growth of yoshida sarcoma 61.6%. Coriolin A has no inhibitory effect on Ehrlich ascites carcinoma in animals .
    Coriolin A
  • HY-N14029
    Coriolin B

    		Bacterial Infection Cancer
    Coriolin B has anti-Gram-positive bacteria, negative bacteria (weak), yeast and vaginal trichomoniasis activities. Coriolin B of 5 μg/mL can inhibit the growth of yoshida sarcoma 61.6%. Coriolin B has no inhibitory effect on Ehrlich ascites carcinoma in animals .
    Coriolin B
  • HY-N14030
    Coriolin C

    		Bacterial Infection Cancer
    Coriolin C has anti-Gram-positive bacteria, negative bacteria (weak), yeast and vaginal trichomoniasis activities. Coriolin C of 5 μg/mL can inhibit the growth of yoshida sarcoma 61.6%. Coriolin C has no inhibitory effect on Ehrlich ascites carcinoma in animals .
    Coriolin C
  • HY-113031S
    16α-Hydroxydehydroepiandrosterone-d6

    16α-hydroxy-DHEA-d6; 16α-OH-DHEA-d6

    		 Isotope-Labeled Compounds Endogenous Metabolite Others
    16α-Hydroxydehydroepiandrosterone-d6 (16α-Hydroxy-DHEA-d6) is the deuterium labeled 16α-Hydroxydehydroepiandrosterone .
    16α-Hydroxydehydroepiandrosterone-d6
  • HY-144273
    IDO1-IN-13

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-13 (compound 27a) is a potent IDO1 inhibitor with an IC50 of 61.6 nM. IDO1-IN-13 has cellular IDO1 inhibition (HeLa EC50= 30 nM). IDO1-IN-13 decreases 51% of the kyn/trp ratio in SK-OV-3 xenograft tumor tissues .
    IDO1-IN-13
  • HY-RS04723
    FAM83D Human Pre-designed siRNA Set A

    CHICA; C20orf129; dJ616B8.3

    		 Small Interfering RNA (siRNA) Others

    FAM83D Human Pre-designed siRNA Set A contains three designed siRNAs for FAM83D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FAM83D Human Pre-designed siRNA Set A
    FAM83D Human Pre-designed siRNA Set A
  • HY-112534
    GSTO-IN-2
    2 Publications Verification

    		 Glutathione S-transferase Cancer
    GSTO-IN-2 is a glutathione S-transferase inhibitor with IC50s of 3.6, 16.3, and 1.4 μM for GSTA2, GSTM1, and GSTP1-1.
    GSTO-IN-2
  • HY-110143
    CLP257

    		Potassium Channel Neurological Disease
    CLP257 is a selective K +-Cl cotransporter KCC2 activator with an EC50 of 616 nM. CLP257 is inactive against NKCC1, GABAA receptors, KCC1, KCC3 or KCC4. CLP257 restores impaired Cl transport in neurons with diminished KCC2 activity. CLP257 alleviates hypersensitivity in rats with neuropathic pain. CLP257 modulates plasmalemmal KCC2 protein turnover post-translationally .
    CLP257
  • HY-149497
    HDAC6-IN-19

    		HDAC Cancer
    HDAC6-IN-19 (Compound 14g) is a HDAC6 inhibitor (IC50: 2.68 nM). HDAC6-IN-19 also inhibits HDAC1, HDAC2 and HDAC3 with IC50s of 61.6 nM, 98.7 nM and 103 nM. HDAC6-IN-19 potently inhibits multiple cancer cell proliferation, including leukemia, colon cancer, melanoma, and breast cancer cell lines .
    HDAC6-IN-19
  • HY-165052
    1,3-Didocosahexaenoyl-2-palmitoyl glycerol

    1,3-Didocosahexaenoin-2-palmitin; DPD; TG(22:6/16:0/22:6)

    		 Others Others
    1,3-Didocosahexaenoyl-2-palmitoyl glycerol (1,3-Didocosahexaenoin-2-palmitin) is a compound that is being studied as a triglyceride positional isomer in fish and marine mammals. The fatty acid binding position of 1,3-Didocosahexaenoyl-2-palmitoyl glycerol varies in different organisms, which may be related to the substrate preference of related enzymes.
    1,3-Didocosahexaenoyl-2-palmitoyl glycerol
  • HY-N14163
    Diperamycin

    		Bacterial Infection Cancer
    Diperamycin has activity against Gram-positive bacteria, including Enterococcus seriolicida and MRSA (MICs of 0.10-0.20 μg/mL). Diperamycin also strongly inhibits the activity of L1210, P388, LS-180, KB, HeLaS3, Meth A and B16-BL6 (IC50s of 0.009-0.098 μg/mL) .
    Diperamycin
  • HY-145827
    KIF18A-IN-4

    		Kinesin Microtubule/Tubulin Cancer
    KIF18A-IN-4 is a moderately potent ATP and microtubule (MT) noncompetitive KIF18A inhibitor (IC50=6.16 μM). KIF18A-IN-4 has selectivity against a large panel of mitotic kinesins and kinases, and does not show any direct effects on tubulin assembly. KIF18A-IN-4 exhibits anti-tumor activity .
    KIF18A-IN-4
  • HY-W754400
    Mannosan,95%-13C6

    1,6-Anhydro-β-D-mannopyranose-13C6

    		 Isotope-Labeled Compounds Biochemical Assay Reagents Others
    Mannosan,95%- 13C6 (1,6-Anhydro-β-D-mannopyranose- 13C6) is the 13C-labeled Mannosan,95% (HY-124095). Mannosan,95% (1,6-Anhydro-β-D-mannopyranose,95%) is a class of biochemical reagents used in glycobiology research. Glycobiology studies the structure, synthesis, biology, and evolution of sugars. It involves carbohydrate chemistry, enzymology of glycan formation and degradation, protein-glycan recognition, and the role of glycans in biological systems. This field is closely related to basic research, biomedicine, and biotechnology .
    Mannosan,95%-13C6
  • HY-P10428
    E6AP-mimicking peptide

    		HPV Infection
    E6AP-mimicking peptide (compound 13) is a high-affinity, selective, irreversible and potent peptide-based covalent HPV16 E6 inhibitor targeting the 16E6 oncoprotein using a cysteine-reactive acrylamide warhead. E6AP-mimicking peptide has a Ki of 17 nM. E6AP-mimicking peptide targets all residues appearing in the binding pocket of E6 to disrupt the binding interface of 16E6 and E6AP. E6AP-mimicking peptide selectively binds and crosslinks to MBP-16E6 in PBS or a protein mixture .
    E6AP-mimicking peptide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: